Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan, November 5, 2009 -Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has decided to transfer the functions of...
Read more about Transfer of Fermentation and Biotechnology Labs.
Japan, November 5, 2009 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that at the meeting of the Board of...
Read more about Astellas Announces Acquisition of Treasury Stock
Japan, October 26, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has decided to terminate the development of...
Tokyo, Japan, October 16, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it was granted approval for “myasthenia...
Tokyo, Japan, October 16, 2009 - AstraZeneca K.K. (headquarters: Tokyo; President and CEO: Masuhiro Kato) today announced that it received a Japanese manufacturing and marketing approval for...
Tokyo, Japan, October 7, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that Astellas and Boehringer Ingelheim Pharmaceuticals, Inc. (a US...
Read more about Astellas and Boehringer Ingelheim Reach Settlement with Impax on FLOMAX® Patent Case
Tokyo, Japan, September 25, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that Boehringer Ingelheim Pharmaceuticals, Inc. (“
Read more about ASTELLAS ANNOUNCES EXTENSION OF MARKET EXCLUSIVITY IN THE US FOR FLOMAX® CAPSULES
Tokyo, Japan, September 24, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) and its US affiliate Astellas Pharma US, Inc. (headquarters:...
Read more about ASTELLAS FILED LAWSUIT AGAINST VESICARE® GENERICFOR PATENT INFRINGEMENT IN THE US
Tokyo, Japan, September 2, 2009- Astellas Pharma Inc. (“Astellas”, Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi Nogimori) announced today that it has established a fund laboratory...
Tokyo, Japan, August 26, 2009 – Pfizer Japan Inc. (“Pfizer”) and Astellas Pharma Inc. (“Astellas”) today announced that the companies have reached a co-promotion agreement for a...
Read more about Pfizer and Astellas Announce Co-promotion Agreement for Caduet® Combination Tablets
Tokyo, Japan, August 21, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that the groundbreaking ceremony for Fermentation...
Tokyo, Japan, August 21, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has decided to reorganize its drug...
Read more about Reorganization of Drug Discovery Research Functions
As stated in the press release issued on August 11, 2009, Astellas Pharma US, Inc. (“Astellas Pharma US”; headquarters: Deerfield, IL), North American affiliate of Astellas Pharma Inc....
Tokyo, Japan, August 11, 2009- Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that its North American affiliate, Astellas Pharma...
Read more about Astellas Announces the Outcome of its Citizen Petition in the US
Tokyo, Japan, August 4, 2009 - AstraZeneca K.K., the Japanese subsidiary of AstraZeneca PLC and Astellas Pharma Inc. (“Astellas”) today announced that AstraZeneca AB (“AstraZeneca”) and...
Follow us
